Zydus to supply Sagent’s Caffeine Citrate Oral Solution from Jarod
This product is indicated for the short-term treatment of a breathing problem (Apnea) in pre-mature infants
Zydus Lifesciences yesterday announced that it will be manufacturing and supplying Sagent’s Caffeine Citrate Oral Solution in the strength of 60 mg per 3 mL (20 mg per mL) single-dose vial from its injectables facility at Jarod, Gujarat.
The company also notified in a statement that it received the Prior Approval Supplement (PAS) approval from the US Food and Drug Administration (FDA), which allows for a site transfer and manufacturing of the drug at Jarod.
This product is indicated for the short-term treatment of a breathing problem (Apnea) in pre-mature infants. Caffeine blocks certain proteins (adenosine receptors) which leads to improved breathing in these infants, the statement said.